Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed) (c. 2377)

[F1 ANNEX I U.K. LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

Textual Amendments

F1 Substituted by Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

2. Antiparasitic agents U.K.

2.1. Agents acting against endoparasites U.K.

2.1.1. Salicylanilides U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Closantel	Closantel	Bovine	1 000  μg/kg	Muscle
			3 000  μg/kg	Fat
			1 000  μg/kg	Liver
			3 000  μg/kg	Kidney
		Ovine	1 500  μg/kg	Muscle
			2 000  μg/kg	Fat
			1 500  μg/kg	Liver
			5 000  μg/kg	Kidney
[F2 Rafoxanide	Rafoxanide	Bovine	30 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			30 μg/kg	Fat
			10 μg/kg	Liver
			40 μg/kg	Kidney
		Ovine	100 μg/kg	Muscle
			250 μg/kg	Fat
			150 μg/kg	Liver
			150 μg/kg	Kidney]

Textual Amendments

F2 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles) U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Levamisole	Levamisole	Bovine, ovine, porcine, poultry	10 μg/kg	Muscle
			10 μg/kg	Fat
			100 μg/kg	Liver
			10 μg/kg	Kidney

2.1.3. Benzimidazoles and pro-benzimidazoles U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F3 Albendazole	Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole	All ruminants	100  μg/kg	Muscle
			100  μg/kg	Fat
			1 000  μg/kg	Liver
			500  μg/kg	Kidney
			100  μg/kg	Milk]
[F4 Albendazole oxide	Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole	Bovine, ovine	100 μg/kg	Muscle
			100 μg/kg	Fat
			1 000  μg/kg	Liver
			500 μg/kg	Kidney
			100 μg/kg	Milk	]
[F3 Febantel	Sum of extractable residues which may be oxidised to oxfendazole sulphone	All ruminants	50  μg/kg	Muscle
			50  μg/kg	Fat
			500  μg/kg	Liver
			50  μg/kg	Kidney
			10  μg/kg	Milk
Fenbendazole	Sum of extractable residues which may be oxidised to oxfendazole sulphone	All ruminants	50  μg/kg	Muscle
			50  μg/kg	Fat
			500  μg/kg	Liver
			50  μg/kg	Kidney
			10  μg/kg	Milk]
Flubendazole	Sum of flubendazole and (2-amino 1H-benzimidazol-5-yl) (4fluorophenyl) methanone	Porcine, chicken, game birds	50 μg/kg	Muscle
			50 μg/kg	Skin and fat
			400 μg/kg	Liver
			300 μg/kg	Kidney
[F5		Turkey	50 μg/kg	Muscle
			50 μg/kg	Skin and fat
			400 μg/kg	Liver
			300 μg/kg	Kidney	]
	Flubendazole	Chicken	400 μg/kg	Eggs
[F6 Mebendazole	Sum of mebendazole methyl (5-(1-hydroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents	Ovine, caprine, equidae	60 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			60 μg/kg	Fat
			400 μg/kg	Liver
			60 μg/kg	Kidney]
[F7 Netobimin	Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole	[X1 Bovine, ovine]	100 μg/kg	Muscle	For oral use only
			100 μg/kg	Fat
			1 000  μg/kg	Liver
			500 μg/kg	Kidney
			100 μg/kg	Milk]
[F3 Oxfendazole	Sum of extractable residues which may be oxidised to oxfendazole sulphone	All ruminants	50  μg/kg	Muscle
			50  μg/kg	Fat
			500  μg/kg	Liver
			50  μg/kg	Kidney
			10  μg/kg	Milk]
Oxibendazole	Oxibendazole	Porcine	100 μg/kg	Muscle
			500 μg/kg	Skin and fat
			200 μg/kg	Liver
			100 μg/kg	Kidney
[F3 Thiabendazole	Sum of thiabendazole and 5-hydroxythiabendazole	Caprine	100  μg/kg	Muscle
			100  μg/kg	Fat
			100  μg/kg	Liver
			100  μg/kg	Kidney
			100  μg/kg	Milk]
Triclabendazole	Sum of extractable residues that may be oxidised to ketotriclabendazole	Bovine, ovine	100 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			100 μg/kg	Liver
			100 μg/kg	Kidney

Editorial Information

X1 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).

Textual Amendments

F3 Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F4 Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F5 Inserted by Commission Regulation (EC) No 2385/1999 of 10 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F6 Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F7 Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F8 2.1.4. Phenol derivatives including salicylanides U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Nitroxinil	Nitroxinil	Bovine, ovine	400 μg/kg	Muscle
			200 μg/kg	Fat
			20 μg/kg	Liver
			400 μg/kg	Kidney
[F3 Oxyclozanide	Oxyclozanide	All ruminants	20  μg/kg	Muscle
			20  μg/kg	Fat
			500  μg/kg	Liver
			100  μg/kg	Kidney
			10  μg/kg	Milk] ]

Textual Amendments

F8 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F9 2.1.5. Benzenesulphonamides U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Clorsulon	Clorsulon	Bovine	35 μg/kg	Muscle
			100 μg/kg	Liver
			200 μg/kg	Kidney	]

Textual Amendments

F9 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F10 2.1.6. Piperazine derivatives U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Piperazine	Piperazine	Porcine	400 μg/kg	Muscle
			800 μg/kg	Skind and fat
			2 000  μg/kg	Liver
			1 000  μg/kg	Kidney
		Chicken	2 000  μg/kg	Eggs	]

Textual Amendments

F10 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F11 2.1.7. Tetrahydropyrimides U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Morantel	Sum of residues which may be hydrolysed to N-methyl-1,3- propanediamine and expressed as morantel equivalents	Bovine, ovine	100 μg/kg	Muscle
			100 μg/kg	Fat
			800 μg/kg	Liver
			200 μg/kg	Kidney
			50 μg/kg	Milk	]

Textual Amendments

F11 Inserted by Commission Regulation (EC) No 1851/2004 of 25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.2. Agents acting against ectoparasites U.K.

2.2.1. Organophosphates U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F2 Coumafos	Coumafos	Bees	100 μg/kg	Honey	]
Diazinon	Diazinon	Bovine, ovine, caprine	20 μg/kg	Milk
		Bovine, porcine, ovine, caprine	20 μg/kg	Muscle
			700 μg/kg	Fat
			20 μg/kg	Liver
			20 μg/kg	Kidney
[F7 Phoxim	Phoxim	Ovine	50 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			400 μg/kg	Fat
			50 μg/kg	Kidney
		Porcine	20 μg/kg	Muscle
			700 μg/kg	Skin and fat
			20 μg/kg	Liver
			20 μg/kg	Kidney]

2.2.2. Formamidines U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Amitraz	Sum of amitraz and all metabolites containing the 2,4-DMA moiety, expressed as amitraz	Bovine	200 μg/kg	Fat
			200 μg/kg	Liver
			200 μg/kg	Kidney
			10 μg/kg	Milk
		Ovine	400 μg/kg	Fat
			100 μg/kg	Liver
			200 μg/kg	Kidney
			10 μg/kg	Milk
		Porcine	400 μg/kg	Skin and fat
			200 μg/kg	Liver
			200 μg/kg	Kidney
[F4		Bees (honey)	200 μg/kg	Honey	]
[F12		Caprine	200  μg/kg	Fat
			100  μg/kg	Liver
			200  μg/kg	Kidney
			10  μg/kg	Milk	]

Textual Amendments

F12 Inserted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.2.3. Pyrethroids U.K.

a [F13 Further provisions in Commission Directive 98/82/EC are to be observed ( OJ L 290, 29.10.1998, p. 25 ).]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F7 [X1 Cyhalothrin	Cyhalothrin (sum of isomers)	Bovine	500 μg/kg	Fat	Further provisions in Council Directive 94/29/EC are to be observed
			50 μg/kg	Kidney
			50 μg/kg	Milk
Cyfluthrin	Cyfluthrin (sum of isomers)	Bovine	10 μg/kg	Muscle
			50 μg/kg	Fat
			10 μg/kg	Liver
			10 μg/kg	Kidney
			20 μg/kg	Milk] ]
[F14 [F3 Deltamethrin	Deltamethrin	All ruminants	10  μg/kg	Muscle
			50  μg/kg	Fat
			10  μg/kg	Liver
			10  μg/kg	Kidney
			20  μg/kg	Milk]
		[F15 Fin fish	10 μg/kg	Muscle and skin in natural proportions] ]
Flumethrin	Flumethrin (sum of trans-Z isomers)	Bovine	10 μg/kg	Muscle
			150 μg/kg	Fat
			20 μg/kg	Liver
			10 μg/kg	Kidney
			30 μg/kg	Milk
[F16		Ovine	10 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			150 μg/kg	Fat
			20 μg/kg	Liver
			10 μg/kg	Kidney	]
[F13 Permethrin	Permethrin (sum of isomers)	Bovine	50 μg/kg	Muscle
			500 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			50 μg/kg	Milk a	]
[F17 Cypermethrin	Cypermethrin (sum of isomers)	Salmonidae	50 μg/kg	Muscle and skin in natural proportions	]
		[F3 All ruminants	20  μg/kg	Muscle
			200  μg/kg	Fat
			20  μg/kg	Liver
			20  μg/kg	Kidney
			20  μg/kg	Milk a	]
[F18 Alphacypermethrin	Cypermethrin (sum of isomers)	Bovine, ovine	20 μg/kg	Muscle
			200 μg/kg	Fat
			20 μg/kg	Liver
			20 μg/kg	Kidney
			20 μg/kg	Milk] a

Textual Amendments

F13 Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F14 Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F15 Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F16 Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F17 Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F18 Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F19 2.2.4. Acyl urea derivatives U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F20 Diflubenzuron	Diflubenzuron	Salmonidae	1 000  μg/kg	Muscle and skin in natural proportions	]
Teflubenzuron	Teflubenzuron	Salmonidae	500 μg/kg	Muscle and skin in natural proportions	]

Textual Amendments

F20 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F19 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F21 2.2.5. Pyrimidines derivatives U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Dicyclanil	Sum of dicyclanil and 2, 4, 6-triamino-pyrimidine-5-carbonitrile	Ovine	200 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			[F22 150 μg/kg]	Fat
			400 μg/kg	Liver
			400 μg/kg	Kidney]

Textual Amendments

F22 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F21 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F2 2.2.6. Triazine derivatives U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Cyromazine	Cyromazine	Ovine	300 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			300 μg/kg	Fat
			300 μg/kg	Liver
			300 μg/kg	Kidney]

2.3. Agents acting against endo- and ectoparasites U.K.

2.3.1. Avermectins U.K.

Phramacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Abamectin	Avermectin B1a	Bovine	10 μg/kg	Fat
			20 μg/kg	Liver
[F10		Ovine	20 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			50 μg/kg	Fat
			25 μg/kg	Liver
			20 μg/kg	Kidney	]
Doramectin	Doramectin	Bovine	10 μg/kg	Muscle	Not for use in bovine from which milk is produced for human consumption
			150 μg/kg	Fat
			100 μg/kg	Liver
			30 μg/kg	Kidney
		Porcine, ovine	20 μg/kg	Muscle	Not for use in ovine from which milk is produced for human consumption
			100 μg/kg	Fat
			50 μg/kg	Liver
			30 μg/kg	Kidney
[F2		Deer, including reindeer	20 μg/kg	Muscle
			100 μg/kg	Fat
			50 μg/kg	Liver
			30 μg/kg	Kidney	]
[F23 Emamectin	Emamectin B1a	Fin fish	100 μg/kg	Muscle and skin in natural proportions	]
Eprinomectin	Eprinomectin B1a	Bovine	[F24 50 μg/kg]	Muscle
			[F24 250 μg/kg]	Fat
			[F24 1 500  μg/kg]	Liver
			[F24 300 μg/kg]	Kidney
			[F24 20 μg/kg]	Milk
Ivermectin	22, 23-Dihydro-avermectin B1a	Bovine	40 μg/kg	Fat
			100 μg/kg	Liver
		Porcine, ovine, equidae	20 μg/kg	Fat
			15 μg/kg	Liver
		Deer, including reindeer	20 μg/kg	Muscle
			100 μg/kg	Fat
			50 μg/kg	Liver
			20 μg/kg	Kidney
Moxidectin	Moxidectin	Bovine, ovine	50 μg/kg	Muscle
			500 μg/kg	Fat
			100 μg/kg	Liver
			50 μg/kg	Kidney
[F25		Bovine	40 μg/kg	Milk	]
[F9		Equidae	50 μg/kg	Muscle
			500 μg/kg	Fat
			100 μg/kg	Liver
			50 μg/kg	Kidney	]

Textual Amendments

F23 Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F24 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F25 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.4. Agents acting against protozoa U.K.

2.4.1. Triazinetrione derivative U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Toltrazuril	Toltrazuril sulfone	Chicken	100 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			200 μg/kg	Skin and fat
			600 μg/kg	Liver
			400 μg/kg	Kidney
		Turkey	100 μg/kg	Muscle
			200 μg/kg	Skin and fat
			600 μg/kg	Liver
			400 μg/kg	Kidney
[F26		Porcine	100 μg/kg	Muscle
			150 μg/kg	Skin and fat
			500 μg/kg	Liver
			250 μg/kg	Kidney	]

Textual Amendments

F26 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F26 2.4.2. Quinazolone derivatives U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Halofuginone	Halofuginone	Bovine	10 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			25 μg/kg	Fat
			30 μg/kg	Liver
			30 μg/kg	Kidney]

[F15 2.4.3. Carbanilides U.K.

a [F27 Not for use in ovine from which milk is produced for human consumption.] ] ]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Imidocarb	Imidocarb	Bovine	300 μg/kg	Muscle
			50 μg/kg	Fat
			2 000  μg/kg	Liver
			1 500  μg/kg	Kidney
			50 μg/kg	Milk
		[F27 Ovine a	300 μg/kg	Muscle
			50 μg/kg	Fat
			2 000  μg/kg	Liver
			1 500  μg/kg	Kidney	]

Textual Amendments

F27 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).